Evidence map›Paper›PMID 36430828›Full record

ArticleInternational journal of molecular sciences2022

Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.

Tamami Nonaka, Hiroaki Taguchi, Taizo Uda, Emi Hifumi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Special Issue "Development and Synthesis of Biologically Active Compounds".International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Tamami NonakaInstitute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.
Hiroaki TaguchiFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho, Suzuka 510-0293, Japan.ORCID 0000-0003-3183-6380
Taizo UdaNanotechnology Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT), 4-1 Kyudai-shinmachi, Fukuoka 879-5593, Japan.
Emi HifumiInstitute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.
Oita University · JPInstitute of Systems, Information Technologies and Nanotechnologies · JPSuzuka University of Medical Science · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology of 676 Japan, and JST-CREST Programs (Japan Science and Technology Agency). KAKENHI Grant Number 20K21255
6 · The paper itself

Abstract

A catalytic antibody has multiple functions compared with a monoclonal antibody because it possesses unique features to digest antigens enzymatically. Therefore, many catalytic antibodies, including their subunits, have been produced since 1989. The catalytic activities often depend on the preparation methods and conditions. In order to elicit the high catalytic activity of the antibodies, the most preferable methods and conditions, which can be generally applicable, must be explored. Based on this view, systematic experiments using two catalytic antibody light chains, #7TR and H34, were performed by varying the purification methods, pH, and chemical reagents. The experimental results obtained by peptidase activity tests and kinetic analysis, revealed that the light chain's high catalytic activity was observed when it was prepared under a basic condition. These data imply that a small structural modulation of the catalytic antibody occurs during the purification process to increase the catalytic activity while the antigen recognition ability is kept constant. The presence of NaCl enhanced the catalytic activity. When the catalytic light chain was prepared with these preferable conditions, #7TR and H34 hugely enhanced the degradation ability of Amyloid-beta and PD-1 peptide, respectively.

Indexed as

Antibodies, CatalyticAntibodies, MonoclonalAntigensImmunoglobulin Light ChainsKineticsAntibodies, CatalyticAntibodies, MonoclonalAntigensImmunoglobulin Light Chainsamyloid-betacatalytic antibody light chainFRET substrateNi-NTA affinity columnPD-1size-exclusion chromatography

Identifiers

PMID36430828
PMCPMC9697424
OpenAlexW4309738754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.